

Statin Therapy for Patients With Cardiovascular Disease (SPC)

New for 2023

Added

- A direct reference code, Z51.5, for an encounter for palliative care
- Frailty exclusion now requires 2 different dates of service during the measurement year

Updated

Members who died during the measurement year is now a required exclusion

Definition

Percentage of males ages 21–75 and females ages 40–75 during the measurement year who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria:

- Received statin therapy Members who were dispensed at least 1 high- or moderate-intensity statin medication during the measurement year
- Statin adherence 80% Members who remained on a high- or moderate-intensity statin medication for at least 80% of the treatment period.
- **Note:** This adherence component does NOT apply to CMS Star Ratings for Medicare members; only the "Received statin therapy" component is required to be compliant for the SPC Star Measure.

SPC inclusion (event, diagnosis or both)		
Event	Timeframe	
Myocardial infraction (MI)	Year prior to the measurement year	
Coronary artery bypass graft (CABG)	Year prior to the measurement year	
Percutaneous coronary intervention (PCI)	Year prior to the measurement year	
Other revascularization	Year prior to the measurement year	
Diagnosis	Timeframe	
Ischemic vascular disease (IVD)	Both measurement year and year prior to the measurement year	

Important note: The **treatment period** is defined as the earliest prescription dispensing date in the measurement year for any statin medication of at least moderate intensity through the last day of the measurement year.

Plan(s) Affected	Quality Program(s) Affected	Collection and Reporting Method
CommercialMedicaidMedicare	CMS Star Ratings - Only includes the sub-measure for "Received Statin Therapy" NCQA Accreditation NCQA Health Plan Ratings	Administrative



Statin Therapy for Patients With Cardiovascular Disease (SPC) (cont.)

Medications

To comply with this measure, one of the following medications must have been dispensed:

Drug Category	Medications	
High-intensity statin therapy	Atorvastatin 40–80 mgAmlodipine-atorvastatin 40–80 mgRosuvastatin 20–40 mg	Simvastatin 80 mgEzetimibe-simvastatin 80 mg
Moderate-intensity statin therapy	 Atorvastatin 10–20 mg Amlodipine-atorvastatin 10–20 mg Rosuvastatin 5–10 mg Simvastatin 20–40 mg Ezetimibe-simvastatin 20–40 mg 	 Pravastatin 40–80 mg Lovastatin 40 mg Fluvastatin 40–80 mg Pitavastatin 1–4 mg



Statin Therapy for Patients With Cardiovascular Disease (SPC)

Required Exclusion(s)

Exclusion	Timeframe
 Members in hospice or using hospice services Members who died Members receiving palliative care Myalgia, myositis, myopathy or rhabdomyolysis diagnosis: G72.0, G72.2, G72.9, M60.80, M60.811, M60.812, M60.819, M60.821, M60.822, M60.829, M60.831, M60.832, M60.839, M60.841, M60.842, M60.849, M60.851, M60.852, M60.859, M60.861, M60.862, M60.869, M60.871, M60.872, M60.879, M60.88, M60.89, M60.9, M62.82, M79.10, M79.11, M79.12, M79.18 	Any time during the measurement year
 Cirrhosis: K70.30, K70.31, K71.7, K74.3, K74.4, K74.5, K74.60, K74.69, P78.81 Dispensed at least one prescription for clomiphene End Stage Renal Disease (ESDR): N18.5, N18.6, Z99.2 Dialysis Members with a diagnosis of pregnancy In vitro fertilization 	Any time during the measurement year or the year prior to the measurement year
Members ages 66 and older as of December 31 of the measurement year who had at least 2 diagnoses of frailty on different dates of service and advanced illness.* Advanced illness is indicated by one of the following:	Frailty diagnoses must be in the measurement year and on different dates of service
 Two or more outpatient, observation, emergency room, telephone, e-visits, virtual check-ins or non-acute inpatient encounters or discharge(s) on separate dates of service with a diagnosis of advanced illness One or more acute inpatient encounter(s) with a diagnosis of advanced illness One or more acute inpatient discharge(s) with a diagnosis of advanced illness on the discharge claim Dispensed a dementia medication: Donepezil, Donepezil-memantine, 	Advanced illness diagnosis must be in the measurement year or year prior to the measurement year
galantamine, rivastigmine or memantine Medicare members ages 66 and older as of Dec. 31 of the measurement year	Any time during the measurement year
who are either: • Enrolled in an Institutional Special Needs Plan (I-SNP) • Living long term in an institution*	

^{*} Supplemental and medical record data may not be used for the frailty with advanced illness or institutional living exclusions.



Statin Therapy for Patients With Cardiovascular Disease (SPC)

Tips and Best Practices to Help Close the "Received Statin Therapy" Care Opportunity for UnitedHealthcare Medicare Advantage Plan Members:

- Please check your Patient Care Opportunity Report (PCOR) often. Look in the Member Adherence tab to find members with open care opportunities.
- Log on to Practice Assist to review members with open care opportunities.
 - Select Medication Adherence to view your patient list.
 - Members without a high- or moderate-intensity statin fill this year will be marked with a "Gap" under the SPC measure.
- Consider prescribing a high- or moderate-intensity statin, as appropriate. If you determine medication is appropriate, please send a prescription to the member's preferred pharmacy.*
 - To address the SPC care opportunity, a member must use their insurance card to fill one of the statins or statin combinations in the strengths/doses listed in the "Medications" table on the previous page by the end of the measurement year.

^{*}Member may use any pharmacy in the network, but may not receive preferred retail pharmacy pricing. Pharmacies in the Preferred Retail Pharmacy Network may not be available in all areas. Co-pays apply after deductible.